Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Shim (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), M. Pyo (Seoul, Republic of Korea), K. Moon (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), J. Choi (Seoul, Republic of Korea), H. Kwon (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea). Progesterone-induced blocking factor as a potential therapeutic target for elderly women with asthma. 1419

Member's Comments

No comment yet.

Related content which might interest you: Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Attenuating future risks in children with active asthma Source: International Congress 2019 – State of the art session: Paediatric respiratory diseases Year: 2019 Can YKL-40 be used as a biomarker and therapeutic target for adult asthma? Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017 Year: 2018 The risk factors contributing asthma development in children Source: Eur Respir J 2002; 20: Suppl. 38, 144s Year: 2002 YS5: The influence of glucocorticoid therapy on trancription factor balance in asthma patients Source: Lung Science Conference 2011 - Immune system dysregulation in chronic lung disease Year: 2011 Further and new evidence-aspects of rhinitis as a risk factor for asthma-onset in adults Source: Eur Respir J 2001; 18: Suppl. 33, 201s Year: 2001 Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention Source: Virtual Congress 2020 – Reducing the burden of asthma Year: 2020 No therapeutic disadvantage for girls with asthma related symptoms Source: Annual Congress 2007 - Epidemiology of paediatric asthma: genes, environment and prognosis Year: 2007 Is asthma a risk factor for COVID-19? Are phenotypes important? Source: ERJ Open Res, 7 (1) 00216-2020; 10.1183/23120541.00216-2020 Year: 2021 Is asthma a risk factor for severe outcomes in COVID 19? Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Is OSA an important risk factor for metabolic dysregulation in obese COPD patients Source: International Congress 2018 – From continuous positive airway pressure (CPAP) and adherence to CPAP to asthma-COPD overlap syndrome (ACOS) Year: 2018 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Using community pharmacy to identify patients at risk of poor asthma control and potential contributory factors Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011 Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019 Current smoking and low HRQoL as strong predictive factors for acute care among elderly asthma patients Source: Annual Congress 2012 - Asthma management Year: 2012 The airway compaints and asthma development (ARCADE) predictive follow-up study: recruiting young children with high-risk of developing asthma in general practice Source: Eur Respir J 2007; 30: Suppl. 51, 381s Year: 2007 The influence of multiple intervention factors on the secretion of Th-cells in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020